APPLICATION OF RANOLAZIN IN COMBINATION WITH AT LEAST ONE AGENT OF JOINT REMODELING IN THE TREATMENT OF HEART FAILURE

摘要

1. A method for reversing harmful remodeling of the left ventricle, comprising administering to a mammal in need thereof a therapeutically effective amount of ranolazine and a therapeutically effective amount of at least one joint remodeling agent. The method of claim 1, wherein the co-remodeling agent comprises an ACE inhibitor, ARB, or a beta blocker. The method of claim 2, wherein the co-remodeling agent comprises an ACE inhibitor. The method of claim 3, wherein the ACE inhibitor is selected from the group consisting of benazepril, captopril, silazapril, enalapril, fosinopril, imidapril, lisinopril, perindopril, guinapril, ramipril, temocapril and trandolapril. The method of claim 2, wherein the co-remodeling agent comprises ARB.6. The method of claim 5, wherein the ARB is selected from the group consisting of candesartan, silexetil, eprosartan, irbesartan, losartan, olmesartan, medoxomil, telmisartan, valsartan, zolasartin and tasosartan. The method of claim 2, wherein the co-remodeling agent comprises a beta blocker. The method according to claim 7, wherein the beta blocker is selected from the group consisting of acebutolol, atenolol, betaxolol, bisoprolol, cartolol, labetalol, metoprolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, timolol, esmolol, sotalol medol carved bucindolol, levobunolol, metipranolol, seliprolol and propafenone. 9. The method of claim 2, wherein the remodeling of the left ventricle is the result of congestive heart failure (CHF) and / or chronic heart failure. The method of claim 1, wherein the ranolazine and co-remodeling agent are administered in separate dosage forms. The method of claim 1, wherein